{"id":64110,"date":"2026-04-28T11:08:00","date_gmt":"2026-04-28T03:08:00","guid":{"rendered":"https:\/\/flcube.com\/?p=64110"},"modified":"2026-04-28T11:08:01","modified_gmt":"2026-04-28T03:08:01","slug":"hinova-pharmaceuticals-reports-positive-phase-iia-results-for-hp515-in-mash-treatment-first-thr-%ce%b2-agonist-candidate-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64110","title":{"rendered":"Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment \u2013 First THR-\u03b2 Agonist Candidate in China"},"content":{"rendered":"\n<p><strong>Hinova Pharmaceuticals Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688302:SHA\">SHA: 688302<\/a>) announced positive interim results from its <strong>Phase IIa clinical study<\/strong> evaluating <strong>HP515<\/strong>, an oral <strong>thyroid hormone receptor beta subtype (THR-\u03b2) agonist<\/strong>, for the treatment of <strong>metabolic dysfunction-associated steatohepatitis (MASH)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-results-summary\">Clinical Trial Results Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>HP515 Treatment Groups<\/th><th>Placebo Group<\/th><th>Statistical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Liver Fat Content (LFC) Reduction<\/strong><\/td><td>Significant reduction at Week 12<\/td><td>Minimal change<\/td><td>P &lt; 0.001<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Good safety and tolerability across all dose groups<\/td><td>\u2013<\/td><td>No serious adverse events reported<\/td><\/tr><tr><td><strong>Administration<\/strong><\/td><td>Oral, 12-week duration<\/td><td>\u2013<\/td><td>Well-tolerated regimen<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-mechanism-amp-innovation\">Drug Mechanism &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Compound<\/strong>: HP515, oral THR-\u03b2 agonist<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Direct activation of thyroid hormone receptor beta subtype to enhance hepatocyte lipid metabolism activity<\/li>\n\n\n\n<li><strong>Therapeutic Effects<\/strong>:<\/li>\n\n\n\n<li>Increases hepatic fat metabolism<\/li>\n\n\n\n<li>Reduces lipotoxicity<\/li>\n\n\n\n<li>Improves metabolic-associated steatohepatitis<\/li>\n\n\n\n<li><strong>Market Position<\/strong>: First THR-\u03b2 agonist candidate for MASH in China; no similar approved products currently available in the Chinese market<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-significance\">Development Significance<\/h2>\n\n\n\n<p>The statistically significant reduction in liver fat content across all HP515 dose groups compared to placebo (P &lt; 0.001) demonstrates robust proof-of-concept for THR-\u03b2 targeting in MASH treatment. The favorable safety profile after 12 weeks of oral administration supports progression to later-stage clinical development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity\">Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need<\/strong>: No approved MASH treatments currently available in China<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: Large and growing MASH patient base in China due to increasing metabolic disorders<\/li>\n\n\n\n<li><strong>Competitive Landscape<\/strong>: First-mover advantage for THR-\u03b2 agonist mechanism in Chinese market<\/li>\n\n\n\n<li><strong>Global Context<\/strong>: THR-\u03b2 agonists represent an emerging therapeutic class for MASH with promising clinical data internationally<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p>Hinova&#8217;s successful Phase IIa results position HP515 as a potential breakthrough therapy for MASH in China. The company may explore partnership opportunities for global development given the universal nature of MASH as a therapeutic indication and the validated THR-\u03b2 target mechanism.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory pathways, and commercial potential for HP515. Actual outcomes may differ due to risks including final trial results, regulatory decisions, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688302_20260428_HR7B.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688302_20260428_HR7B.\"><\/object><a id=\"wp-block-file--media-fc03197b-db21-4c31-ac44-9d5c568a5b5e\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688302_20260428_HR7B.pdf\">688302_20260428_HR7B<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/688302_20260428_HR7B.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-fc03197b-db21-4c31-ac44-9d5c568a5b5e\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Hinova Pharmaceuticals Inc. (SHA: 688302) announced positive interim results from its Phase IIa clinical study&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,331,76,1140],"class_list":["post-64110","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hinova-pharmaceuticals","tag-nash","tag-sha-688302"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment \u2013 First THR-\u03b2 Agonist Candidate in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hinova Pharmaceuticals Inc. (SHA: 688302) announced positive interim results from its Phase IIa clinical study evaluating HP515, an oral thyroid hormone receptor beta subtype (THR-\u03b2) agonist, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64110\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment \u2013 First THR-\u03b2 Agonist Candidate in China\" \/>\n<meta property=\"og:description\" content=\"Hinova Pharmaceuticals Inc. (SHA: 688302) announced positive interim results from its Phase IIa clinical study evaluating HP515, an oral thyroid hormone receptor beta subtype (THR-\u03b2) agonist, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64110\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T03:08:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T03:08:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64110#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64110\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment \u2013 First THR-\u03b2 Agonist Candidate in China\",\"datePublished\":\"2026-04-28T03:08:00+00:00\",\"dateModified\":\"2026-04-28T03:08:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64110\"},\"wordCount\":335,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"Hinova Pharmaceuticals\",\"NASH\",\"SHA: 688302\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64110#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64110\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64110\",\"name\":\"Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment \u2013 First THR-\u03b2 Agonist Candidate in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-28T03:08:00+00:00\",\"dateModified\":\"2026-04-28T03:08:01+00:00\",\"description\":\"Hinova Pharmaceuticals Inc. (SHA: 688302) announced positive interim results from its Phase IIa clinical study evaluating HP515, an oral thyroid hormone receptor beta subtype (THR-\u03b2) agonist, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64110#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64110\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64110#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment \u2013 First THR-\u03b2 Agonist Candidate in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment \u2013 First THR-\u03b2 Agonist Candidate in China - Insight, China&#039;s Pharmaceutical Industry","description":"Hinova Pharmaceuticals Inc. (SHA: 688302) announced positive interim results from its Phase IIa clinical study evaluating HP515, an oral thyroid hormone receptor beta subtype (THR-\u03b2) agonist, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64110","og_locale":"en_US","og_type":"article","og_title":"Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment \u2013 First THR-\u03b2 Agonist Candidate in China","og_description":"Hinova Pharmaceuticals Inc. (SHA: 688302) announced positive interim results from its Phase IIa clinical study evaluating HP515, an oral thyroid hormone receptor beta subtype (THR-\u03b2) agonist, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).","og_url":"https:\/\/flcube.com\/?p=64110","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-28T03:08:00+00:00","article_modified_time":"2026-04-28T03:08:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64110#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64110"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment \u2013 First THR-\u03b2 Agonist Candidate in China","datePublished":"2026-04-28T03:08:00+00:00","dateModified":"2026-04-28T03:08:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64110"},"wordCount":335,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","Hinova Pharmaceuticals","NASH","SHA: 688302"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64110#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64110","url":"https:\/\/flcube.com\/?p=64110","name":"Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment \u2013 First THR-\u03b2 Agonist Candidate in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-28T03:08:00+00:00","dateModified":"2026-04-28T03:08:01+00:00","description":"Hinova Pharmaceuticals Inc. (SHA: 688302) announced positive interim results from its Phase IIa clinical study evaluating HP515, an oral thyroid hormone receptor beta subtype (THR-\u03b2) agonist, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64110#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64110"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64110#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hinova Pharmaceuticals Reports Positive Phase IIa Results for HP515 in MASH Treatment \u2013 First THR-\u03b2 Agonist Candidate in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64110","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64110"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64110\/revisions"}],"predecessor-version":[{"id":64112,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64110\/revisions\/64112"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64110"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64110"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64110"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}